Aclarion, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACON research report →
Price Chart
About the company
Aclarion, Inc. , a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications.
- CEO
- Brent Ness
- IPO
- 2022
- Employees
- 11
- HQ
- Broomfield, CA, US
Get TickerSpark's AI analysis on ACON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43M
- P/E
- -0.35
- PEG
- -0.00
- P/S
- 17.13
- P/B
- 0.39
- EV/EBITDA
- 1.66
- Div Yield
- 0.00%
- Gross Margin
- -50.96%
- Op Margin
- -11592.14%
- Net Margin
- -10978.48%
- ROE
- -59.34%
- ROIC
- -57.11%
Latest fiscal year · YoY change
- Revenue
- $75.73K+65.6%
- Gross Profit
- $-220,578-162.5%
- Op Income
- $-7,052,391
- Net Income
- $-7,233,629-3.4%
- EPS
- $-13.61+99.8%
- OCF Growth
- -35.9%
- FCF Growth
- -28.5%
- 52W High
- $12.03
- 52W Low
- $1.95
- 50D MA
- $2.67
- 200D MA
- $3.80
- Beta
- 1.22
- RSI (14)
- 56
- Avg Volume
- 72.65K
No earnings-call transcripts are available for ACON yet.
- Free Float
- 100.0%
- Shares Outstanding
- 533.31K
- Float Shares
- 533.28K
of shares held by institutions
8 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Clear Street LLC | 3 | 0 |
Held by 4 ETFs
Biggest fund positions in ACON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Williams Amanda M | buy | 5,857 |
| Aug 14, 26 | Gould Gregory A | buy | 10,000 |
| Aug 13, 26 | Bond Ryan | buy | 21,122 |
| Aug 13, 26 | Wesemann William | buy | 2,150 |
| Aug 13, 26 | Neal David K | buy | 7,500 |
| Aug 13, 26 | Ness Brent | buy | 5,234 |
| Jun 11, 26 | Bond Ryan | other | 55,000 |
| Jun 11, 26 | Sequira Amanda Mae | other | 20,000 |
| Jun 11, 26 | Breidbart Scott | other | 20,000 |
| Jun 11, 26 | Gould Gregory A | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACON coverage
Recent articles, reports, and earnings notes.
No research on ACON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACON report →Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
globenewswire.com · Aug 20
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
prismmediawire.com · Aug 12
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
globenewswire.com · Aug 12
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Aug 6
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
prismmediawire.com · Aug 4
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
globenewswire.com · Aug 4
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
prismmediawire.com · Jul 29
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
globenewswire.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.